HBW Advisory Services LLC Has $2.07 Million Position in Amgen Inc. $AMGN

Key Points

• HBW Advisory Services LLC cut its stake in Amgen by 32.7% in Q4, selling 3,080 shares and holding 6,337 shares worth about $2.07 million per its latest 13F filing.
• Analyst sentiment is mixed-to-neutral: MarketBeat shows a consensus rating of Hold with an average price target of $355.84, though several firms have recently raised targets (some up to $400) and issued Buy/outperform views.
• Amgen recently beat quarterly estimates with EPS of $5.29 and revenue of $9.87B, set FY2026 guidance of 21.60–23.00 EPS, and announced a quarterly dividend of $2.52 per share (annualized $10.08, yield 2.9%, ex-dividend May 15).

HBW Advisory Services LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 32.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,337 shares of the medical research company's stock after selling 3,080 shares during the period. HBW Advisory Services LLC's holdings in Amgen were worth $2,074,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. West Family Investments Inc. lifted its stake in shares of Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company's stock valued at $779,000 after purchasing an additional 30 shares during the last quarter. Viawealth LLC lifted its stake in shares of Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company's stock valued at $2,023,000 after purchasing an additional 30 shares during the last quarter. LOM Asset Management Ltd lifted its stake in shares of Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock valued at $721,000 after purchasing an additional 30 shares during the last quarter. Sittner & Nelson LLC lifted its stake in shares of Amgen by 0.4% in the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company's stock valued at $2,053,000 after purchasing an additional 30 shares during the last quarter. Finally, ORG Partners LLC lifted its stake in shares of Amgen by 0.6% in the 4th quarter. ORG Partners LLC now owns 5,398 shares of the medical research company's stock valued at $1,767,000 after purchasing an additional 31 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company lifted their price objective on shares of Amgen from $375.00 to $390.00 and gave the company an "equal weight" rating in a research note on Thursday, March 19th. Argus lifted their target price on shares of Amgen from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, February 6th. Oppenheimer set a $400.00 target price on shares of Amgen and gave the stock an "outperform" rating in a report on Thursday, January 29th. Guggenheim lifted their target price on shares of Amgen from $347.00 to $351.00 and gave the stock a "neutral" rating in a report on Thursday. Finally, Daiwa Securities Group lifted their target price on shares of Amgen from $370.00 to $410.00 and gave the stock an "outperform" rating in a report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $355.84.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: China approval for tarlatamab expands Amgen’s lung-cancer market access and supports future revenue in a large oncology market — a meaningful commercial win for a new oncology asset. Amgen's lung cancer drug tarlatamab wins China approval
• Positive Sentiment: Phase‑4 FORWARD II gout study update: a less‑frequent Krystexxa dosing schedule could improve patient adherence and lifetime drug value, which would be positive for product uptake and revenue stability. Amgen’s FORWARD II Gout Study
• Positive Sentiment: Analyst bullishness on fundamentals: Zacks argues Amgen is poised to beat earnings again, supported by its recent history of surprise results and solid guidance — this can underpin near‑term sentiment ahead of the next report. Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
• Positive Sentiment: Royal Bank of Canada raised its price target to $370, signaling upside from some institutional analysts and suggesting conviction in Amgen’s mid‑term growth drivers. Royal Bank Of Canada Increases Amgen Price Target
• Neutral Sentiment: Guggenheim nudged its target to $351 while retaining a neutral rating — little immediate directional impact given the price is near that level. Amgen Price Target Raised to $351 at Guggenheim
• Neutral Sentiment: Short‑interest data reported for April appears inconsistent/erroneous (reads as 0 shares / NaN increase), so it’s unlikely to be a reliable driver of today’s action. (data entry)
• Neutral Sentiment: Media pieces highlighting Amgen’s profitability and recent TEPEZZA subcutaneous Phase‑3 topline results reinforce the company’s longer‑term value story but are incremental to near‑term price moves. Is Amgen One of the Most Profitable Value Stocks?
• Negative Sentiment: Morgan Stanley’s latest stance (equal‑weight, target raised only to $326) and other hold ratings emphasize limited near‑term upside vs. current levels — that analyst positioning is weighing on the stock. Morgan Stanley equal weight on Amgen

Amgen Stock Performance

NASDAQ:AMGN opened at $350.92 on Monday. The firm's 50-day moving average is $363.87 and its 200-day moving average is $335.48. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a market cap of $189.39 billion, a price-to-earnings ratio of 24.66, a PEG ratio of 3.30 and a beta of 0.47.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the previous year, the firm posted $5.31 EPS. The business's revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen's payout ratio is presently 70.84%.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.